BusinessCombination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical TrialBy Nasdaq OMXNov 13, 2017, 1:31 PM UTC
